RETRACTED ARTICLE: Investigating EGFR-VEGF-mediated apoptotic effect of cucurbitacin D and I combination with sorafenib via Ras/Raf/MEK/ERK and PI3K/Akt signaling pathways

Naunyn Schmiedebergs Arch Pharmacol. 2024 May;397(5):3247. doi: 10.1007/s00210-023-02811-z. Epub 2023 Nov 2.
No abstract available

Publication types

  • Retracted Publication

MeSH terms

  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / pharmacology
  • Apoptosis* / drug effects
  • Cell Line, Tumor
  • ErbB Receptors* / metabolism
  • Extracellular Signal-Regulated MAP Kinases / metabolism
  • Humans
  • Niacinamide / administration & dosage
  • Niacinamide / analogs & derivatives
  • Niacinamide / pharmacology
  • Phenylurea Compounds* / administration & dosage
  • Phenylurea Compounds* / pharmacology
  • Phosphatidylinositol 3-Kinases / metabolism
  • Proto-Oncogene Proteins c-akt* / metabolism
  • Signal Transduction* / drug effects
  • Sorafenib* / administration & dosage
  • Sorafenib* / pharmacology
  • Triterpenes* / administration & dosage
  • Triterpenes* / pharmacology
  • Vascular Endothelial Growth Factor A* / metabolism
  • raf Kinases* / metabolism
  • ras Proteins / metabolism

Substances

  • Sorafenib
  • Proto-Oncogene Proteins c-akt
  • ErbB Receptors
  • Phenylurea Compounds
  • Triterpenes
  • Vascular Endothelial Growth Factor A
  • raf Kinases
  • Phosphatidylinositol 3-Kinases
  • Niacinamide
  • ras Proteins
  • Antineoplastic Agents
  • Extracellular Signal-Regulated MAP Kinases
  • EGFR protein, human